Sumitomo Corporation Sponsored ADR logo

Sumitomo Corporation Sponsored ADR (SSUMY)

Market Closed
10 Aug, 20:00
OTC PINK OTC PINK
$
11. 24
-0.21
-1.8341%
$
51.64B Market Cap
9.27 P/E Ratio
0.82% Div Yield
53,480 Volume
0 Eps
$ 11.45
Previous Close
Investors:
Add Transaction
Day Range
11.24 11.43
Year Range
6.55 12.21
Want to track SSUMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Is Sumitomo (SSUMY) Stock Outpacing Its Conglomerates Peers This Year?

Is Sumitomo (SSUMY) Stock Outpacing Its Conglomerates Peers This Year?

Here is how Sumitomo Corp. (SSUMY) and Swire Pacific (SWRAY) have performed compared to their sector so far this year.

Zacks | 4 months ago
SSUMY vs. ITT: Which Stock Is the Better Value Option?

SSUMY vs. ITT: Which Stock Is the Better Value Option?

Investors with an interest in Diversified Operations stocks have likely encountered both Sumitomo Corp. (SSUMY) and ITT (ITT). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 4 months ago
Jefferies gains on reports of potential Sumitomo Mitsui takeover interest

Jefferies gains on reports of potential Sumitomo Mitsui takeover interest

Shares of Jefferies Group (NYSE:JEF) rose on Tuesday after reports that Japan's Sumitomo Mitsui Financial Group is preparing plans for a possible takeover of the US investment bank. Jefferies has indicated it is not interested in selling, CNBC reported Tuesday morning.

Proactiveinvestors | 4 months ago
SSUMY vs. HON: Which Stock Should Value Investors Buy Now?

SSUMY vs. HON: Which Stock Should Value Investors Buy Now?

Investors interested in Diversified Operations stocks are likely familiar with Sumitomo Corp. (SSUMY) and Honeywell International Inc. (HON). But which of these two stocks is more attractive to value investors?

Zacks | 5 months ago
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript

Seekingalpha | 5 months ago
Are Conglomerates Stocks Lagging Sumitomo (SSUMY) This Year?

Are Conglomerates Stocks Lagging Sumitomo (SSUMY) This Year?

Here is how Sumitomo Corp. (SSUMY) and Swire Pacific (SWRAY) have performed compared to their sector so far this year.

Zacks | 5 months ago
What Makes Sumitomo Corp. (SSUMY) a Strong Momentum Stock: Buy Now?

What Makes Sumitomo Corp. (SSUMY) a Strong Momentum Stock: Buy Now?

Does Sumitomo Corp. (SSUMY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 6 months ago
What Makes Sumitomo (SSUMY) a New Buy Stock

What Makes Sumitomo (SSUMY) a New Buy Stock

Sumitomo (SSUMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 6 months ago
SSUMY or HON: Which Is the Better Value Stock Right Now?

SSUMY or HON: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Diversified Operations sector might want to consider either Sumitomo Corp. (SSUMY) or Honeywell International Inc. (HON). But which of these two stocks presents investors with the better value opportunity right now?

Zacks | 6 months ago
Is Sumitomo (SSUMY) Stock Undervalued Right Now?

Is Sumitomo (SSUMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 6 months ago
Mitsui Sumitomo Continues to Build WR Berkley Stake

Mitsui Sumitomo Continues to Build WR Berkley Stake

A beneficial owner continues to build a stake in W.R.

247wallst | 6 months ago
Sumitomo Mitsui: Still A 'Buy' Considering Semiconductor Opportunities

Sumitomo Mitsui: Still A 'Buy' Considering Semiconductor Opportunities

I still rate Sumitomo Mitsui Financial a "Buy" after analyzing its growth and capital return prospects. SMFG raised its full-year net income guidance by 15% to ¥1,500 billion, which is reflective of strong semis-related deal flow. The stock offers a 4.4% forward shareholder yield, considering its raised dividend guidance and expanded buyback program.

Seekingalpha | 7 months ago
Loading...
Load More